Vocal cord haematoma after tenecteplase thrombolysis.
At present, thrombolysis remains the principal reperfusion strategy for ST-elevation acute coronary syndromes in most countries, due to the limited availability of primary angioplasty. Haemorrhagic complications, which are among the most frequent side effects, are usually not very important. As a matter of fact, 70% of the bleeding takes place at venepuncture sites and does not require special treatment. We report an unusual case of vocal cord haematoma after thrombolysis with tenecteplase in a patient with acute myocardial infarction. As far as we know, this type of side effect has only been described once in the literature, namely, after thrombolysis with tissue plasminogen activator in deep vein thrombosis.
Samimi-Fard
Sima
S
Coronary Care Unit, Department of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Garcia-Gonzalez
Martin
M
Dominguez-Rodriguez
Alberto
A
D000368:Aged; D003328:Coronary Thrombosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004562:Electrocardiography / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006406:Hematoma / Q000139:chemically induced*; D006801:Humans; D007818:Laryngeal Diseases / Q000139:chemically induced*; D007828:Laryngoscopy; D008297:Male; D000077785:Tenecteplase; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use; D014827:Vocal Cords; D014832:Voice Disorders / Q000139:chemically induced
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase